Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk
Authors:
- Michael R. McClungMMMichael R. McClung
- Donald BetahDBDonald Betah
- Cynthia DeignanCDCynthia Deignan
- Yifei ShiYSYifei Shi
- Jen TimoshankoJTJen Timoshanko
- Felicia CosmanFCFelicia Cosman
Open Access
- 3 July 2023
- journal article
- research article
- Published by Elsevier in Endocrine Practice
- Vol. 29 (9) , 716-722
Abstract
No abstract availableKeywords
Funding Information
- UCB Pharma SA
- Astellas Pharma
- Amgen
This publication has 21 references indexed in Scilit:
- Romosozumab or Alendronate for Fracture Prevention in Women with OsteoporosisNew England Journal of Medicine, 2017
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trialThe Lancet, 2017
- Imminent risk of fracture after fractureOsteoporosis International, 2016
- Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for OsteoporosisJournal of Bone and Mineral Research, 2016
- Romosozumab Treatment in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2016
- Romosozumab in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2014
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Diagnostic criteria for primary osteoporosis: year 2000 revisionJournal of Bone and Mineral Metabolism, 2001
- Diagnostic criteria of primary osteoporosisJournal of Bone and Mineral Metabolism, 1998
- Updated Data on Proximal Femur Bone Mineral Levels of US AdultsOsteoporosis International, 1998